We next evaluated the antitumoral activity of the ERK-mTOR targeting combination therapy in vivo, using UM-SCC-17B and Detroit 562 HNSCC xenografts, which harbor endogenous activating HRAS and PIK3CA mutations, respectively. Here, HRAS is linked to head and neck squamous cell carcinoma.